Venturing into Biotechnology (Hosted by EFCIE)
Starting any new venture as an entrepreneur is challenging, however there are some unique considerations for a start-up or spin-off in biotech. This presentation will describe the process of evaluating a new idea or technology and the formation of a new company, aspects that are specific to biotech development including the time and capital typically needed to get to a commercial product, how far the founder is going to take this towards that goal as the company scales up, and some of the difficult decisions to be made along the way. Strategies for managing risks will be discussed, along with practical advice for finding support, mentors, and ideally investors to enable your vision to become a viable company going forward.
Michael Parr, Ph.D.
President and Chief Scientific Officer @Sitka Biopharma
Michael Parr is the President and Chief Scientific Officer of Sitka Biopharma. With more than 15 years of experience in the industry, Dr. Parr has played a key role in developing and guiding a number of programs into clinical trials. Prior to founding Sitka, Dr. Parr spent 6 years as the Director for Commercial Project Development at CDRD Ventures Inc. (CVI), where he was responsible for developing and managing the CVI portfolio. From 2006-2008, he served as Program Manager at Angiotech Pharmaceuticals, guiding two late-stage novel biomaterial-based drug products in oncology and pain indications toward IND submissions. Previously, Dr. Parr served in a variety of roles of increasing responsibility during his 7 years at Biogen-Idec, most recently as Associate Director of Oncology. Dr. Parr earned a PhD in Biochemistry and Molecular Biology from the University of British Columbia and completed post-doctoral training at Harvard University.